We are live on ! Find out more
FHTX icon

Foghorn Therapeutics
FHTX

59 hedge funds and large institutions have $170M invested in Foghorn Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more capital invested

Capital invested by funds: $135M → $170M (+$35M)

6% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 17

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2.03% less ownership

Funds ownership: 64.32% → 62.29% (-2%)

3% less funds holding

Funds holding: 61 → 59 (-2)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

Holders
59
Holders Change
-2
Holders Change %
-3.28%
% of All Funds
0.86%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
18
Reduced
17
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
RJA
Raymond James & Associates
Florida
+$2.77M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.1M
3
Morgan Stanley
Morgan Stanley
New York
+$595K
4
SCM
Sio Capital Management
New York
+$525K
5
PAM
Panagora Asset Management
Massachusetts
+$269K

Top Sellers

1
AG
Artal Group
Luxembourg
-$4.31M
2
DM
Deerfield Management
New York
-$3.89M
3
GW
GW & Wade
Massachusetts
-$539K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$381K
5
BlackRock
BlackRock
New York
-$371K
Name Holding Trade Value Shares
Change 		Change in
Stake
AWA
26
Alta Wealth Advisors
Massachusetts
$194K +$130K +30,032 New
Bank of America
27
Bank of America
North Carolina
$188K +$66.3K +15,375 +112%
RhumbLine Advisers
28
RhumbLine Advisers
Massachusetts
$167K -$2.01K -465 -2%
CIC
29
Cornercap Investment Counsel
Georgia
$167K – – –
UBS Group
30
UBS Group
Switzerland
$151K +$55.8K +12,945 +124%
ETC
31
Exchange Traded Concepts
Oklahoma
$139K +$23.6K +5,460 +34%
Goldman Sachs
32
Goldman Sachs
New York
$91.9K -$7.38K -1,710 -11%
HSBC Holdings
33
HSBC Holdings
United Kingdom
$90.5K +$69 +16 +0.1%
JP Morgan Chase
34
JP Morgan Chase
New York
$85K -$33.8K -7,841 -37%
Jane Street
35
Jane Street
New York
$82.9K +$55.4K +12,851 New
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$73.1K -$86.3K -20,007 -64%
FT
37
Fiduciary Trust
Massachusetts
$70.2K – – –
AIG
38
American International Group
New York
$65.2K -$177 -41 -0.4%
AllianceBernstein
39
AllianceBernstein
Tennessee
$64.8K -$3.02K -700 -7%
Deutsche Bank
40
Deutsche Bank
Germany
$64.5K – – –
Lazard Asset Management
41
Lazard Asset Management
New York
$57K +$38.7K +8,982 New
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$42K +$1.32K +307 +5%
Wells Fargo
43
Wells Fargo
California
$34K +$5.18K +1,200 +30%
Nisa Investment Advisors
44
Nisa Investment Advisors
Missouri
$32.3K +$19.1K +4,437 +788%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$21.6K -$4.91K -1,139 -25%
AB
46
Amalgamated Bank
New York
$19K -$876 -203 -7%
Citigroup
47
Citigroup
New York
$18.9K +$10.3K +2,388 +438%
Legal & General Group
48
Legal & General Group
United Kingdom
$13K – – –
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$12.1K -$138 -32 -2%
AIP
50
Ameritas Investment Partners
Nebraska
$9.89K – – –
1
2
3

FHTX Hedge Fund Activity: Q4 2023 in Review

59 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q4 2023, worth a combined $170M — up 26% from $135M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of FHTX and 6 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 18 added.

The largest buyer was Raymond James & Associates, adding an estimated $2.77M. The largest seller was Artal Group, cutting an estimated $4.31M.

  • 59 institutional investors held Foghorn Therapeutics (FHTX) as of Q4 2023, down from 61 in Q3 2023.
  • Funds reported $170M of Foghorn Therapeutics stock for Q4 2023, up 26% quarter-over-quarter.
  • 6 funds opened new Foghorn Therapeutics positions in Q4 2023 and 8 closed out, a net change of -2 holders.
  • The largest Foghorn Therapeutics buyer in Q4 2023 was Raymond James & Associates, an estimated $2.77M added.
  • The largest Foghorn Therapeutics seller in Q4 2023 was Artal Group, an estimated $4.31M sold.

Based on aggregated 13F filings for Q4 2023.